Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

被引:5
作者
Sugawara, Kotaro [1 ]
Fukuda, Takashi [1 ]
Murakami, Chiaki [2 ,3 ]
Oka, Daiji [1 ]
Yoshii, Takako [4 ]
Amori, Gulanbar [2 ,5 ,6 ]
Ishibashi, Kumiko [2 ]
Kobayashi, Yasuhito [2 ]
Hara, Hiroki [4 ]
Kanda, Hiroaki [2 ]
Motoi, Noriko [2 ,7 ]
机构
[1] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan
[2] Saitama Canc Ctr, Dept Pathol, 780 Komuro, Ina, Saitama 3620806, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan
[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp JFCR, Dept Pathol, Tokyo, Japan
[7] Saitama Canc Ctr, Ctr Canc Genom Med, Saitama, Japan
关键词
esophageal squamous cell carcinoma; immune checkpoint inhibitor; neoadjuvant chemotherapy; surgery; tumor microenvironment; INFILTRATING LYMPHOCYTES; CANCER; EXPRESSION; SURVIVAL; THERAPY;
D O I
10.1111/cas.16203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of immune checkpoint inhibitors (ICIs), a better understanding of tumor microenvironment (TME) is becoming crucial in managing esophageal squamous cell carcinoma (ESCC) patients. We investigated the survival impact of TME status and changes in patients with ESCC who underwent neoadjuvant chemotherapy (NAC) followed by surgery (n = 264). We examined immunohistochemical status (CD4+, CD8+, CD20+, Foxp3+, HLA class-1+, CD204+, and programmed death ligand-1 [PD-L1+]) on 264 pre-NAC and 204 paired post-NAC specimens. Patients were classified by their pre- and post-NAC immune cell status and their changes following NAC. Our findings showed that pre-NAC TME status was not significantly associated with survival outcomes. In contrast, post-NAC TME status, such as low level of T cells, CD4+ T cells, and high PD-L1 combined positive score (CPS), were significantly associated with poor overall survival (OS). Notably, TME changes through NAC exerted significant survival impacts; patients with consistently low levels of T cells, low levels of CD4+ T cells, or high levels of PD-L1 (CPS) had very poor OS (3-year OS: 35.5%, 40.2%, and 33.3%, respectively). Tumor microenvironment changes of consistently low T cells, low CD4+ T cells, and high PD-L1 were independent predictors of poor OS in multivariate Cox hazards analyses, while factors indicating post-NAC status (T cells, CD4+, and PD-L1 [CPS]) alone were not. Therefore, we suggest that the consistently low T/high PD-L1 group could benefit from additional therapies, such as ICIs, and the importance of stratification by the TME, which has recently been recognized. Tumor microenvironment after neoadjuvant chemotherapy (NAC), such as low T cells, low CD4+ cells, or high programmed death ligand-1 [PD-L1], were significantly associated with poor survival in patients with esophageal squamous cell carcinoma. Importantly, immune cell changes following NAC, such as consistently low T cells, consistently low CD4+ cells, or persistently high PD-L1, were independent predictors for poor survival.image
引用
收藏
页码:2819 / 2830
页数:12
相关论文
共 49 条
[1]   Epidemiology of Esophageal Squamous Cell Carcinoma [J].
Abnet, Christian C. ;
Arnold, Melina ;
Wei, Wen-Qiang .
GASTROENTEROLOGY, 2018, 154 (02) :360-373
[2]   A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) [J].
Ando, Nobutoshi ;
Kato, Hoichi ;
Igaki, Hiroyasu ;
Shinoda, Masayuki ;
Ozawa, Soji ;
Shimizu, Hideaki ;
Nakamura, Tsutomu ;
Yabusaki, Hiroshi ;
Aoyama, Norio ;
Kurita, Akira ;
Ikeda, Kenichiro ;
Kanda, Tatsuo ;
Tsujinaka, Toshimasa ;
Nakamura, Kenichi ;
Fukuda, Haruhiko .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) :68-74
[3]  
Brierley JD, 2017, TNM classification of malignant tumours
[4]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[5]   Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma [J].
Doki, Y. ;
Ajani, J. A. ;
Kato, K. ;
Xu, J. ;
Wyrwicz, L. ;
Motoyama, S. ;
Ogata, T. ;
Kawakami, H. ;
Hsu, C. -H. ;
Adenis, A. ;
El Hajbi, F. ;
Di Bartolomeo, M. ;
Braghiroli, M. I. ;
Holtved, E. ;
Ostoich, S. A. ;
Kim, H. R. ;
Ueno, M. ;
Mansoor, W. ;
Yang, W. -C. ;
Liu, T. ;
Bridgewater, J. ;
Makino, T. ;
Xynos, I. ;
Liu, X. ;
Lei, M. ;
Kondo, K. ;
Patel, A. ;
Gricar, J. ;
Chau, I. ;
Kitagawa, Y. .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05) :449-462
[6]   Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial [J].
Eyck, Ben M. ;
van Lanschot, J. Jan B. ;
Hulshof, Maarten C. C. M. ;
van der Wilk, Berend J. ;
Shapiro, Joel ;
van Hagen, Pieter ;
Henegouwen, Mark I. van Berge ;
Wijnhoven, Bas P. L. ;
van Laarhoven, Hanneke W. M. ;
Nieuwenhuijzen, Grard A. P. ;
Hospers, Geke A. P. ;
Bonenkamp, Johannes J. ;
Cuesta, Miguel A. ;
Blaisse, Reinoud J. B. ;
Busch, Olivier R. ;
Creemers, Geert-Jan M. ;
Punt, Cornelis J. A. ;
Plukker, John Th M. ;
Verheul, Henk M. W. ;
Bilgen, Ernst J. Spillenaar ;
van der Sangen, Maurice J. C. ;
Rozema, Tom ;
Ten Kate, Fiebo J. W. ;
Beukema, Jannet C. ;
Piet, Anna H. M. ;
van Rij, Caroline M. ;
Reinders, Janny G. ;
Tilanus, Hugo W. ;
Steyerberg, Ewout W. ;
van der Gaast, Ate .
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18) :1995-+
[7]   Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma [J].
Fukuoka, Eiji ;
Yamashita, Kimihiro ;
Tanaka, Tomoko ;
Sawada, Ryuichiro ;
Sugita, Yutaka ;
Arimoto, Akira ;
Fujita, Mitsugu ;
Takiguchi, Gosuke ;
Matsuda, Takeru ;
Oshikiri, Taro ;
Nakamura, Tetsu ;
Suzuki, Satoshi ;
Kakeji, Yoshihiro .
ANTICANCER RESEARCH, 2019, 39 (08) :4539-4548
[8]   Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients [J].
Gao, Yibo ;
Guo, Wei ;
Geng, Xiao ;
Zhang, Yidong ;
Zhang, Guochao ;
Qiu, Bin ;
Tan, Fengwei ;
Xue, Qi ;
Gao, Shugeng ;
He, Jie .
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (13)
[9]   Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer A Systematic Review and Meta-analysis [J].
Ge, Fan ;
Huo, Zhenyu ;
Cai, Xiuyu ;
Hu, Qiyuan ;
Chen, Wenhao ;
Lin, Guo ;
Zhong, Ran ;
You, Zhending ;
Wang, Rui ;
Lu, Yi ;
Wang, Runchen ;
Huang, Qinhong ;
Zhang, Haotian ;
Song, Aiqi ;
Li, Caichen ;
Wen, Yaokai ;
Jiang, Yu ;
Liang, Hengrui ;
He, Jianxing ;
Liang, Wenhua ;
Liu, Jun .
JAMA NETWORK OPEN, 2022, 5 (11) :E2239778
[10]   Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy [J].
Goto, Wataru ;
Kashiwagi, Shinichiro ;
Asano, Yuka ;
Takada, Koji ;
Takahashi, Katsuyuki ;
Hatano, Takaharu ;
Takashima, Tsutomu ;
Tomita, Shuhei ;
Motomura, Hisashi ;
Ohsawa, Masahiko ;
Hirakawa, Kosei ;
Ohira, Masaichi .
ESMO OPEN, 2018, 3 (06)